FORM 4
[ X ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
OMB APPROVAL
OMB Number: 3235-0287
Expires: February 28, 2011
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934, Section 17(a) of the Public
Utility Holding Company Act of 1935 or Section 30(f) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

WATSON DOUGLAS G 		2. Issuer Name and Ticker or Trading Symbol

JAVELIN PHARMACEUTICALS, INC [ JAV ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

__ X __ Director                      _____ 10% Owner
_____ Officer (give title below)      _____ Other (specify below)
(Last)          (First)          (Middle)

C/O JAVELIN PHARMACEUTICALS, INC, 125 CAMBRIDGEPARK DRIVE 		3. Date of Earliest Transaction (MM/DD/YYYY)

6/30/2010
(Street)

CAMBRIDGE, MA 02140
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
6. Individual or Joint/Group Filing (Check Applicable Line)

_ X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock   6/30/2010     U    20000   (1) D $2.20   0   D    

Table II - Derivative Securities Beneficially Owned ( e.g. , puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3) 		2. Conversion or Exercise Price of Derivative Security 3. Trans. Date 3A. Deemed Execution Date, if any 4. Trans. Code
(Instr. 8) 		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		6. Date Exercisable and Expiration Date 7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4) 		8. Price of Derivative Security
(Instr. 5) 		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
Stock Option (right to buy)   $5.4   7/2/2010     D         50921   (2)   12/6/2004   3/31/2012   Common Stock   50921   $0   0   D    
Stock Option (right to buy)   $1.96   7/2/2010     D         35644   (3)   12/6/2004   8/22/2013   Common Stock   35644   $0   0   D    
Stock Option (right to buy)   $2.7   7/2/2010     D         45000   (2)   4/12/2006   4/12/2015   Common Stock   45000   $0   0   D    
Stock Option (right to buy)   $4.05   7/2/2010     D         105000   (2)     (4) 3/8/2016   Common Stock   105000   $0   0   D    
Stock Option (right to buy)   $4.98   7/2/2010     D         35000   (2)   1/2/2008   1/3/2017   Common Stock   35000   $0   0   D    
Stock Option (right to buy)   $3.53   7/2/2010     D         35000   (2)     (5) 1/9/2018   Common Stock   35000   $0   0   D    
Stock Option (right to buy)   $1.26   7/2/2010     D         24000   (6)   12/31/2009   5/1/2019   Common Stock   24000   $0   0   D    
Stock Option (right to buy)   $1.19   7/2/2010     D         24000   (7)   6/23/2010   6/23/2019   Common Stock   24000   $0   0   D    

Explanation of Responses:
( 1)  Pursuant to the Agreement and Plan of Merger, dated April 17, 2010, by and among Hospira, Inc., Discus Acquisition Corporation ("Purchaser") and Javelin Pharmaceuticals, Inc. (the "Company"), Purchaser merged with and into the Company on July 2, 2010 (the "Merger"). These shares, which were outstanding immediately prior to the effective time of the Merger (the "Effective Time"), were immediately canceled and converted at the effective time of the Merger into the right to receive cash consideration equal to $2.20 per share.
( 2)  These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled and terminated.
( 3)  These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $8,554.56, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 4)  55,000 of the options vested and were exersicable on March 8, 2007, 25,000 of the options vested and were exercisable on March 8, 2008 and 25,000 of the options vested and were exercisable on March 8, 2009.
( 5)  The shares underlying this option vest and become exercisable in three equal annual installments begining on 1/9/2009.
( 6)  These options, which were outstanding and unexercised immediately prior to the Effective Time, accelerated and were immediately canceled, terminated and converted into the right to receive a cash payment of $22,560.00, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.
( 7)  These options, which were outstanding, unexercised and fully vested immediately prior to the Effective Time were immediately canceled, terminated and converted into the right to receive a cash payment of $24,240.00, representing (a) the difference between the exercise price of the option and the merger consideration of $2.20 per share multiplied by (b) the number of shares subject to the option.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director 10% Owner Officer Other
WATSON DOUGLAS G
C/O JAVELIN PHARMACEUTICALS, INC
125 CAMBRIDGEPARK DRIVE
CAMBRIDGE, MA 02140 		X



Signatures
/s/ Douglas G. Watson 7/2/2010
** Signature of Reporting Person Date


Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4(b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
Javelin Pharmaceuticals (AMEX:JAV)
Gráfica de Acción Histórica
De Nov 2024 a Dic 2024 Haga Click aquí para más Gráficas Javelin Pharmaceuticals.
Javelin Pharmaceuticals (AMEX:JAV)
Gráfica de Acción Histórica
De Dic 2023 a Dic 2024 Haga Click aquí para más Gráficas Javelin Pharmaceuticals.